ArticleAdvances in therapy2025
Disease Burden and Treatment Patterns Amongst Patients with Haemophilia A in China: A Retrospective Database Analysis Study.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The therapeutic landscape of inherited bleeding disorders in China.Research and practice in thrombosis and haemostasis · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
introductionDespite concerted efforts of healthcare agencies, haemophilia treatment coverage remains inadequate in China. This real-world study was conducted to understand patient characteristics, clinical and economic burden, and treatment patterns amongst patients with haemophilia A in China with the aim of improving patient outcomes and quality of life.
methodsTwo data sources, namely the National Haemophilia Registry and Institute of Haematology and Blood Diseases Hospital, were used to analyse the disease burden, treatment patterns and economic burden of haemophilia A in China. The economic burden was assessed from 2017 to 2019.
resultsOverall, 3164 male patients with haemophilia A (mean age 21.5 years) were analysed. Almost half (48.3%) of the patients were children or adolescents; amongst them, 13.5% were enrolled from Guangdong and 10.7% from Hebei. Furthermore, 58.9% of the patients had severe haemophilia A. The most common sites for the first bleeding and bleeding during disease course were skin/mucous membrane (40.0%) and joints (77.9%), respectively. Plasma-derived factor VIII constituted the most frequently used therapy (45.8% of patients) and only 30.1% of patients used a prophylactic treatment. The hospitalisation rate increased from 8% in 2017 to 21% in 2019, whereas 63% to 75% of patients had outpatient visits during each year. The total annual cost of treating haemophilia (hospitalisation plus outpatient) including the cost of FVIII replacement per patient was 57,439.4 CNY.
conclusionSuboptimal disease management and low utilisation of prophylaxis are the main challenges for patients with haemophilia A in China. Therefore, continued efforts to improve disease awareness and treatment accessibility are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.